Pasithea Therapeutics -CW26KTTAWPreferred / convertible
13F holders, Q3 2025 (September 30)5holders
1new positions
0sold out
1famous investor
$0.02avg. 13F price*
At the end of Q3 2025, 5 institutions reported holding Pasithea Therapeutics -CW26 (KTTAW) in their 13F filings, unchanged from Q2 2025. 1 opened new positions and 0 sold out. The largest holders were Kepos Capital LP ($6K), Armistice Capital, LLC ($845) and Marex Group Ltd ($423). One famous investor held it Ken Griffin ( of Citadel Advisors's portfolio).
- Company
- Pasithea Therapeutics -CW26
- CUSIP
- 70261F111
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $247 |
| Exits | 0 | $0 |
All 13F filers, Q2 2025 → Q3 2025: 14,586 shares bought and 320 shares sold, net +14,266 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| Kepos Capital LP | — | No change | 334,600 | $6K |
| Armistice Capital, LLC | — | No change | 50,000 | $845 |
| Marex Group Ltd | — | No change | 25,000 | $423 |
| Susquehanna International Group, LLP | — | New | 14,586 | $247 |
| Citadel Advisors | — | Reduce -2.1% | 15,191 | $207 |
"% of holder's portfolio" is KTTAW's weight in each manager's 13F, not the share of Pasithea Therapeutics -CW26 the manager owns.